vs
普尔斯马特（PSMT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
普尔斯马特的季度营收约是Revvity的1.8倍（$1.4B vs $772.1M），Revvity净利率更高（12.7% vs 2.9%，领先9.8%），普尔斯马特同比增速更快（9.9% vs 5.9%），Revvity自由现金流更多（$161.8M vs $32.6M），过去两年Revvity的营收复合增速更高（9.0% vs 3.5%）
PriceSmart（普尔斯马特）是一家美资会员制仓储商超运营商，业务覆盖中美洲、加勒比地区及南美洲。公司由Price Club的创立者索尔·普莱斯与罗伯特·普莱斯共同创办，罗伯特·普莱斯现任董事会主席。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PSMT vs RVTY — 直观对比
营收规模更大
PSMT
是对方的1.8倍
$772.1M
营收增速更快
PSMT
高出4.1%
5.9%
净利率更高
RVTY
高出9.8%
2.9%
自由现金流更多
RVTY
多$129.2M
$32.6M
两年增速更快
RVTY
近两年复合增速
3.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $772.1M |
| 净利润 | $40.2M | $98.4M |
| 毛利率 | 17.7% | — |
| 营业利润率 | 4.6% | 14.5% |
| 净利率 | 2.9% | 12.7% |
| 营收同比 | 9.9% | 5.9% |
| 净利润同比 | 7.3% | 3.9% |
| 每股收益（稀释后） | $1.29 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PSMTRVTY
| Q4 25 | $1.4B | $772.1M | ||
| Q3 25 | $1.3B | $698.9M | ||
| Q2 25 | $1.3B | $720.3M | ||
| Q1 25 | $1.4B | $664.8M | ||
| Q4 24 | $1.3B | $729.4M | ||
| Q3 24 | $1.2B | $684.0M | ||
| Q2 24 | $1.2B | $691.7M | ||
| Q1 24 | $1.3B | $649.9M |
净利润PSMTRVTY
| Q4 25 | $40.2M | $98.4M | ||
| Q3 25 | $31.5M | $46.7M | ||
| Q2 25 | $35.2M | $53.9M | ||
| Q1 25 | $43.8M | $42.2M | ||
| Q4 24 | $37.4M | $94.6M | ||
| Q3 24 | $29.1M | $94.4M | ||
| Q2 24 | $32.5M | $55.4M | ||
| Q1 24 | $39.3M | $26.0M |
毛利率PSMTRVTY
| Q4 25 | 17.7% | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | 17.1% | 56.5% | ||
| Q4 24 | 17.4% | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率PSMTRVTY
| Q4 25 | 4.6% | 14.5% | ||
| Q3 25 | 4.0% | 11.7% | ||
| Q2 25 | 4.3% | 12.6% | ||
| Q1 25 | 4.8% | 10.9% | ||
| Q4 24 | 4.6% | 16.3% | ||
| Q3 24 | 4.0% | 14.3% | ||
| Q2 24 | 4.1% | 12.4% | ||
| Q1 24 | 4.9% | 6.8% |
净利率PSMTRVTY
| Q4 25 | 2.9% | 12.7% | ||
| Q3 25 | 2.4% | 6.7% | ||
| Q2 25 | 2.7% | 7.5% | ||
| Q1 25 | 3.2% | 6.4% | ||
| Q4 24 | 3.0% | 13.0% | ||
| Q3 24 | 2.4% | 13.8% | ||
| Q2 24 | 2.6% | 8.0% | ||
| Q1 24 | 3.0% | 4.0% |
每股收益（稀释后）PSMTRVTY
| Q4 25 | $1.29 | $0.86 | ||
| Q3 25 | $1.02 | $0.40 | ||
| Q2 25 | $1.14 | $0.46 | ||
| Q1 25 | $1.45 | $0.35 | ||
| Q4 24 | $1.21 | $0.77 | ||
| Q3 24 | $0.94 | $0.77 | ||
| Q2 24 | $1.08 | $0.45 | ||
| Q1 24 | $1.31 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $320.6M | $919.9M |
| 总债务越低越好 | $180.3M | — |
| 股东权益账面价值 | $1.3B | $7.3B |
| 总资产 | $2.4B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.14× | — |
8季度趋势，按日历期对齐
现金及短期投资PSMTRVTY
| Q4 25 | $320.6M | $919.9M | ||
| Q3 25 | $314.2M | $931.4M | ||
| Q2 25 | $262.4M | $991.8M | ||
| Q1 25 | $247.3M | $1.1B | ||
| Q4 24 | $222.2M | $1.2B | ||
| Q3 24 | $225.5M | $1.2B | ||
| Q2 24 | $228.2M | $2.0B | ||
| Q1 24 | $264.2M | $1.7B |
总债务PSMTRVTY
| Q4 25 | $180.3M | — | ||
| Q3 25 | $186.6M | — | ||
| Q2 25 | $103.1M | — | ||
| Q1 25 | $107.1M | — | ||
| Q4 24 | $115.6M | — | ||
| Q3 24 | $130.4M | — | ||
| Q2 24 | $135.1M | — | ||
| Q1 24 | $140.0M | — |
股东权益PSMTRVTY
| Q4 25 | $1.3B | $7.3B | ||
| Q3 25 | $1.2B | $7.4B | ||
| Q2 25 | $1.2B | $7.6B | ||
| Q1 25 | $1.2B | $7.6B | ||
| Q4 24 | $1.2B | $7.7B | ||
| Q3 24 | $1.1B | $7.9B | ||
| Q2 24 | $1.1B | $7.9B | ||
| Q1 24 | $1.1B | $7.8B |
总资产PSMTRVTY
| Q4 25 | $2.4B | $12.2B | ||
| Q3 25 | $2.3B | $12.1B | ||
| Q2 25 | $2.1B | $12.4B | ||
| Q1 25 | $2.1B | $12.4B | ||
| Q4 24 | $2.1B | $12.4B | ||
| Q3 24 | $2.0B | $12.8B | ||
| Q2 24 | $2.0B | $13.4B | ||
| Q1 24 | $2.0B | $13.4B |
负债/权益比PSMTRVTY
| Q4 25 | 0.14× | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 0.08× | — | ||
| Q1 25 | 0.09× | — | ||
| Q4 24 | 0.10× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.12× | — | ||
| Q1 24 | 0.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $71.2M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $32.6M | $161.8M |
| 自由现金流率自由现金流/营收 | 2.4% | 21.0% |
| 资本支出强度资本支出/营收 | 2.8% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.77× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $125.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流PSMTRVTY
| Q4 25 | $71.2M | $182.0M | ||
| Q3 25 | $82.1M | $138.5M | ||
| Q2 25 | $52.8M | $134.3M | ||
| Q1 25 | $87.9M | $128.2M | ||
| Q4 24 | $38.5M | $174.2M | ||
| Q3 24 | $41.8M | $147.9M | ||
| Q2 24 | $38.1M | $158.6M | ||
| Q1 24 | $86.6M | $147.6M |
自由现金流PSMTRVTY
| Q4 25 | $32.6M | $161.8M | ||
| Q3 25 | $25.6M | $120.0M | ||
| Q2 25 | $14.0M | $115.5M | ||
| Q1 25 | $53.2M | $112.2M | ||
| Q4 24 | $10.3M | $149.8M | ||
| Q3 24 | $15.2M | $125.6M | ||
| Q2 24 | $-308.0K | $136.6M | ||
| Q1 24 | $16.4M | $129.7M |
自由现金流率PSMTRVTY
| Q4 25 | 2.4% | 21.0% | ||
| Q3 25 | 1.9% | 17.2% | ||
| Q2 25 | 1.1% | 16.0% | ||
| Q1 25 | 3.9% | 16.9% | ||
| Q4 24 | 0.8% | 20.5% | ||
| Q3 24 | 1.2% | 18.4% | ||
| Q2 24 | -0.0% | 19.7% | ||
| Q1 24 | 1.3% | 20.0% |
资本支出强度PSMTRVTY
| Q4 25 | 2.8% | 2.6% | ||
| Q3 25 | 4.2% | 2.6% | ||
| Q2 25 | 2.9% | 2.6% | ||
| Q1 25 | 2.5% | 2.4% | ||
| Q4 24 | 2.2% | 3.4% | ||
| Q3 24 | 2.2% | 3.3% | ||
| Q2 24 | 3.1% | 3.2% | ||
| Q1 24 | 5.4% | 2.7% |
现金转化率PSMTRVTY
| Q4 25 | 1.77× | 1.85× | ||
| Q3 25 | 2.60× | 2.97× | ||
| Q2 25 | 1.50× | 2.49× | ||
| Q1 25 | 2.01× | 3.03× | ||
| Q4 24 | 1.03× | 1.84× | ||
| Q3 24 | 1.44× | 1.57× | ||
| Q2 24 | 1.17× | 2.87× | ||
| Q1 24 | 2.20× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PSMT
| Fresh Foods | $454.9M | 33% |
| Caribbean Operations Segment | $396.5M | 29% |
| Colombia Operations Segment | $204.1M | 15% |
| Hardlines | $162.6M | 12% |
| Softlines | $99.8M | 7% |
| ship Income Member | $24.5M | 2% |
| Health Services | $14.5M | 1% |
| Other Revenue And Income | $4.2M | 0% |
| United States Operations Segment | $510.0K | 0% |
| Export Sales | $359.0K | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
